AQST · Aquestive Therapeutics, Inc.
$4.25
+0.00 (+0.00%)
At close · Aug 14
Market Cap
$533.42M
Shares
125.51M
Aquestive Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Aquestive Therapeutics, Inc. (AQST) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼13.7%
$11.46M
−$12.54M
'22 Q3
22-11-01
▼3.6%
$10.68M
−$12.35M
'22 Q4
23-03-07
▼9.3%
$11.13M
$8.07M
'23 Q1
23-05-02
▼0.2%
$13.24M
−$5.79M
'23 Q2
23-08-07
▲13.4%
$13.00M
−$2.04M
'23 Q3
23-11-06
▲23.6%
$13.21M
−$8.11M
'23 Q4
24-03-05
▲8.3%
$12.05M
−$12.83M
'24 Q1
24-05-07
▲51.8%
$20.10M
−$2.75M
'24 Q2
24-08-06
▲4.2%
$13.54M
−$11.51M
'24 Q3
24-11-04
▼10.1%
$11.87M
−$17.05M
'24 Q4
25-03-05
▼27.7%
$8.72M
−$22.93M
'25 Q1
25-05-12
▼50.2%
$10.00M
−$13.55M
'25 Q2
25-08-11
▼5.4%
$12.81M
−$15.45M
'25 Q3
25-11-05
▲9.7%
$13.02M
−$31.86M
'25 Q4
26-03-04
▲65.7%
$14.45M
−$8.06M
'26 Q1
26-05-14
LATEST
▲38.1%
$13.82M
−$22.86M
'26 Q2
26-08-12
Earnings call
FY26 · Q2
2026-08-12
Aquestive Therapeutics, Inc. Q2 FY2026 Earnings Call
Revenue
$13.82M
▲ 38.1% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
Aquestive Therapeutics, Inc. Q1 FY2026 Earnings Call
Confident tone
FDA Review and Expedited Pathways
Anifilm NDA Resubmission Timeline
AQST-108 Pipeline and TSLP Biomarker
Revenue
$14.45M
▲ 65.7% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Aquestive Therapeutics, Inc. Q4 FY2025 Earnings Call
Confident tone
ANNAFILM NDA resubmission and FDA path
Commercial launch readiness
Capital and financing
Revenue
$13.02M*
▲ 9.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Aquestive Therapeutics, Inc. Q3 FY2025 Earnings Call
Positive tone
Pipeline program AQST-108 / Adrenaverse
Anifilm FDA resubmission and review timing
Commercial launch preparation
Revenue
$12.81M
▼ 5.4% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Aquestive Therapeutics, Inc. Q2 FY2025 Earnings Call
Positive tone
Anaphylm FDA review and approval timeline
Launch financing and capital position
Payer access barriers and patient-first approach
Revenue
$10.00M
▼ 50.2% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Aquestive Therapeutics, Inc. Q1 FY2025 Earnings Call
Confident tone
Anaphylm FDA review and launch preparation
Payer engagement and existing Libervant contracts
Commercial team and marketing buildout
Revenue
$8.72M
▼ 27.7% YoY Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-05
Aquestive Therapeutics, Inc. Q4 FY2024 Earnings Call
Confident tone
Libervant commercial and legal risk
Sales force and commercial launch planning
Awareness trial and usage study (ATU)
Revenue
$11.87M*
▼ 10.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Aquestive Therapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone
Anaphylm regulatory progress and FDA alignment
Libervant commercial launch and market access
OASIS study results for Anaphylm
Revenue
$13.54M
▲ 4.2% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Aquestive Therapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone
Anaphylm development and regulatory progress
Libervant launch and expansion
Financial guidance and cash position
Revenue
$20.10M
▲ 51.8% YoY Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Aquestive Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone
Anaphylm clinical progress and filing timeline
Libervant FDA approval and commercial rollout (2 to 5)
Pediatric study and labeling strategy for Anaphylm
Revenue
$12.05M
▲ 8.3% YoY Diluted EPS
$-0.17
▼ 254.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-05
Aquestive Therapeutics, Inc. Q4 FY2023 Earnings Call
Revenue
$13.21M*
▲ 23.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Aquestive Therapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$13.00M
▲ 13.4% YoY Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Aquestive Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$13.24M
▼ 0.2% YoY Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Aquestive Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$11.13M
▼ 9.3% YoY Diluted EPS
$0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-07
Aquestive Therapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$10.68M*
▼ 3.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Aquestive Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$11.46M
▼ 13.7% YoY Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Aquestive Therapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$13.27M
▼ 13.6% YoY Diluted EPS
$-0.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Aquestive Therapeutics, Inc. Q1 FY2022 Earnings Call
Revenue
$12.27M
▲ 10.3% YoY Diluted EPS
$-0.32
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-08
Aquestive Therapeutics, Inc. Q4 FY2021 Earnings Call
Revenue
$11.08M*
▲ 55% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Aquestive Therapeutics, Inc. Q3 FY2021 Earnings Call
Revenue
$13.29M
▲ 60.9% YoY Diluted EPS
$-0.37
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Aquestive Therapeutics, Inc. Q2 FY2021 Earnings Call
Revenue
$15.35M
▼ 29.2% YoY Diluted EPS
$-0.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Aquestive Therapeutics, Inc. Q1 FY2021 Earnings Call
Revenue
$11.12M
▲ 26.9% YoY Diluted EPS
$-0.41
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-09
Aquestive Therapeutics, Inc. Q4 FY2020 Earnings Call
Revenue
$7.15M
▼ 56.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Aquestive Therapeutics, Inc. Q3 FY2020 Earnings Call
Revenue
$8.26M
▼ 33.5% YoY Diluted EPS
$-0.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Aquestive Therapeutics, Inc. Q2 FY2020 Earnings Call
Revenue
$21.68M
▲ 94.8% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Aquestive Therapeutics, Inc. Q1 FY2020 Earnings Call
Revenue
$8.77M
▼ 30.7% YoY Diluted EPS
$-0.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-11
Aquestive Therapeutics, Inc. Q4 FY2019 Earnings Call
Revenue
$16.42M
▼ 2.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls
Key facts
CIK
1398733
CUSIP
03843E104
13F (30d)
181 filings
177 filers
Visit website
Investor relations